Hipertensão ocular recorrente durante hemodiálise em paciente portador de glaucoma / Recurrent intraocular hypertension during hemodialysis in glaucoma patient

RESUMO A hipertensão ocular aguda durante a hemodiálise constitui evento raro e pode ser causa relevante de interrupção do tratamento dialítico devido à dor. Relata-se o caso de um paciente de 70 anos de idade, do sexo masculino, que apresentou quadros recorrentes de intensa dor ocular unilateral durante sessões dialíticas devido ao aumento de pressão intraocular. O paciente era portador de grave diminuição da acuidade visual no olho direito devido a glaucoma neovascular, controlado com medicação hipotensora tópica. Uma hora após o início da sessão dialítica, apresentou dor excruciante no olho direito, sendo necessário interromper o tratamento por diversas vezes. A dor somente era amenizada com uso de opioides por via endovenosa ou após cerca de 6 horas do procedimento. Injeção intraocular de drogas antiangiogênicas e acetazolamida por via oral, assim como tratamentos tradicionais para quadros agudos de hipertensão intraocular, como uso de hipotensor tópico e medicamentos hiperosmolares, foram insuficientes para o controle da dor. O problema se resolveu com ciclofotocoagulação transescleral realizada com laser diodo, com redução da pressão intraocular basal e controle da dor, o que permitiu a realização de sessões completas de hemodiálise. A base fisiopatológica desse evento incomum e suas opções terapêuticas são discutidas aqui.

ABSTRACT Acute ocular hypertension during hemodialysis is a rare event and may lead to interruption of dialytic therapy due to pain. A case of a 70-year-old male patient is reported, who presented recurrent intense unilateral ocular pain episodes during dialysis sessions for increased intraocular pressure. The patient presented with severely decreased visual acuity in the right eye due to neovascular glaucoma, which was controlled with topical hypotensive medication. One hour after initiating dialysis, he presented an excruciating pain on the right eye, which required interruption of treatment several times. Pain relief was possible only with intravenous opioids, or approximately 6 hours after dialysis. Intraocular injection of antiangiogenic drugs and per oris acetazolamide, as well as other traditional treatments for acute episodes of intraocular hypertension, such as topical antihypertensive agents and hyperosmotic medications, were not sufficient to control pain. The problem was solved with transscleral diode laser cyclophotocoagulation, which reduced baseline intraocular pressure and controlled pain, enabling complete hemodialysis sessions. The pathophysiological aspects and therapeutic options of this unusual condition are discussed.

Tratamento do olho cego doloroso por glaucoma neovascular com ciclofotocoagulação transescleral / Transescleral cyclophotocoagulation treatment for painful eye with glaucoma neovascular

Resumo Objetivo: Avaliar a efetividade e o perfil de segurança da ciclofotocoagulação transescleral padrão (CTCTE) e sua variação técnica denominada slow cooking (CTCTE SC) em pacientes com olho cego doloroso por glaucoma neovascular. Métodos: Pacientes foram submetidos a exame oftalmológico, graduando o nível da dor através de escala gráfica/numérica e divididos em dois grupos, um para tratamento com CTCTE e outro CTCTE SC. O acompanhamento foi realizado no primeiro, trigésimo e nonagésimo dias. Resultados: Dos 26 pacientes inclusos, 11 (42,3%) eram do sexo masculino. A idade média dos pacientes foi de 69 anos. Destes, 16 pacientes foram submetidos ao tratamento CTCTE e 10 pacientes a CTCTE SC. A pressão intraocular (PIO) teve média pré tratamento de 49 ± 23 mmHg no grupo CFCTE e medias no 1º, 30º e 90º dias pós-operatórios respectivamente: 32 ± 24 mmHg, 38 ± 18 mmHg, 43 ± 10 mmHg. No grupo submetido a técnica CFCTE SC a PIO prévia foi 54 ± 16 mmHg e médias no 1º, 30º e 90º dias pós-operatórios respectivamente: 38 ± 22 mmHg, 39 ± 10 mmHg , 44 ± 09 mmHg. A redução da dor foi efetiva em 88,4% pacientes. Durante o pós-operatório foi verificado hiperemia, quemose e hifema. Não foram observadas complicações graves. Conclusão: O tratamento do olho cego doloroso com ciclofotocoagulação transescleral com baixa carga foi um procedimento seguro e eficaz na resolução da dor, mas apresentou um baixo nível de redução da pressão intraocular em ambas técnicas usadas.

Abstract Objective: To evaluate the effectiveness and safety profile of standard transescleral cyclophotocoagulation (CTCTE) and its technical variation of slow cooking (CTCTE SC) in patients with neovascular glaucoma pain. Methods: Patients underwent ophthalmological examination, grading their pain level through a graphical / numerical scale and divided into two groups, one for treatment with CTCTE and another CTCTE SC. Follow-up was performed on the first, thirtieth and ninetieth days. Results: Of the 26 patients included, 11 (42.3%) were male. The average age of the patients was 69 years. Of these, 16 patients underwent CTCTE treatment and 10 patients underwent CTCTE SC. Intraocular pressure (IOP) had a mean pre-treatment of 49 ± 23 mmHg in the CFCTE group and medians at the 1st, 30th and 90th postoperative days respectively: 32 ± 24 mmHg, 38 ± 18 mmHg, 43 ± 10 mmHg. In the group submitted to the CFCTE SC technique, the previous IOP was 54 ± 16 mmHg and averages on the 1st, 30th and 90th postoperative days respectively: 38 ± 22 mmHg, 39 ± 10 mmHg, 44 ± 09 mmHg. Pain reduction was effective in 88.4% patients. During the postoperative period, hyperemia, chemosis and hyphema were observed. No serious complications were observed. Conclusion: Painful blind eye treatment with low load transscleral cyclophotocoagulation was a safe and effective procedure for pain resolution, but presented a low level of intraocular pressure reduction in both techniques used.

Glaucoma neovascular, complicación de la isquemia retiniana / Neovascular glaucoma, a retinal ischemia complication

Introducción: el glaucoma neovascular es un tipo de glaucoma secundario frecuente en los pacientes diabéticos, se produce por la formación de una membrana fibrovascular a nivel del ángulo camerular, como consecuencia de un estímulo angiogénico producido por enfermedades que generan isquemia ocular. Los pacientes con retinopatía diabética proliferativa pueden sufrir esta enfermedad de difícil tratamiento para el oftalmólogo, y que constituye una amenaza para la visión del paciente. Objetivo: revisar aspectos clínicos, patogenia, métodos para el diagnóstico y tratamiento terapéutico del glaucoma neovascular con vistas a prevenir o reducir la pérdida visual. Desarrollo: el glaucoma neovascular es una complicación de la diabetes mellitus y de otras enfermedades generales, que provoca una disminución importante de la visión, y en muchas ocasiones, ceguera. Las enfermedades oculares que con más frecuencia lo producen son la oclusión de la vena central de la retina, la retinopatía diabética proliferativa y el síndrome isquémico ocular, generando isquemia retiniana y coroidea con la consecuente formación de neovasos. Conclusiones: la educación al paciente diabético y el adecuado tratamiento terapéutico de la retinopatía diabética es importante para prevenir la aparición del glaucoma neovascular(AU)

Introduction: neovascular glaucoma is the type of secondary glaucoma common in diabetic patients; it is caused by the formation of fibrovascular membrane at the camerular angle as a result of angiogenic stimulus due to ocular ischemia-generating diseases. The proliferative diabetic retinopathy patients may suffer this difficult-to-treat disease that represents a threat to the vision of a patient. Objective: to review clinical aspects, pathogenenesis, diagnosis methods and treatment of the neovascular glaucoma with a view to preventing or reducing the vision loss. Development: neovascular glaucoma is a complication of diabetes mellitus and of other general diseases, which brings about significant reduction of vision and often blindness. The most frequent eye diseases responsible for this are central retinal vein occlusion, proliferative diabetic retinopathy and ocular ischemic syndrome, leading to retinal and choroid ischemia with resulting formation of neovessels. Conclusions: education aimed at diabetic patient and the adequate therapeutic treatment of the diabetic retinopathy is important to prevent the occurrence of neovascular glaucoma(AU)

Triancinolona intra-vítrea e clorpromazina retrobulbar como alternativas ao manejo do olho cego doloroso / Intravietrea trianciclone and retotubulbar chlorpromazine as alternative to blind paintful eye manegement

RESUMO Objetivo: O objetivo desde estudo foi avaliar a efetividade da triancinolona intra-vítrea e da clorpromazina retrobulbar como alternativas no manejo da dor ocular em olhos cegos. Métodos: Este foi um estudo prospectivo intervencionista não-randomizado de pacientes com olho cego doloroso não responsivo ao tratamento tópico e sem indicação de evisceração atendidos no Serviço de Oftalmologia do Hospital Governador Celso Ramos no ano de 2010. Após exame oftalmológico e ultrassonografia ocular modo B, os pacientes foram divididos em dois grupos. Pacientes do Grupo 1 possuíam glaucoma intratável e receberam injeção retrobulbar de clorpromazina 2,5ml, e pacientes do Grupo 2 possuíam olhos phthisicos com componente inflamatório e receberam injeção intra-vítrea de triancinolona 0,3ml. Foram realizadas avaliações com 1, 3 e 6 meses após o procedimento e a dor quantificada de forma subjetiva em uma escala de 0 a 10 (sem dor e com o máximo de dor, respectivamente). Resultados: Foram incluídos 38 olhos, sendo 15 no Grupo 1 e 21 no Grupo 2. Houve predomínio do sexo masculino e idade média de 54 anos. A causa mais prevalente de olho cego doloroso foi o glaucoma neovascular. Tanto a injeção de clorpromazina retrobulbar quanto a de triancinolona intra-vítrea mostraram-se eficazes no controle da dor ocular em olhos cegos no período do estudo (p<0,001). Ocorreu uma redução de 77,1% no uso de colírios (p<0,01) após a aplicação das medicações. Conclusão: Tanto a injeção de clorpromazina retrobulbar quanto a de triancinolona intra-vítrea mostraram resultados significativos no controle da dor ocular em olhos cegos, além de uma redução no uso de colírios. A clorpromazina é um medicamento de baixo custo, com melhor perfil de efeitos adversos e mostrou resultados discretamente melhores relação à triancinolona. Possíveis viéses identificados no estudo são o de tempo e seleção.

ABSTRACT Objective: The objective of this study was to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes. Methods: This was a non-randomized interventional prospective study of patients with painful blind eye unresponsive to topical treatment and without indication of evisceration treated at the Hospital Governador Celso Ramos Ophthalmology Service in 2010. After ocular examination and ocular B mode ultrasound, patients were divided into two groups. Group 1 patients had intractable glaucoma and received retrobulbar injection of chlorpromazine 2.5ml, and Group 2 patients had phthisics eyes with inflammatory component and received intravitreal triamcinolone injection 0.3ml. Evaluations were performed at 1, 3 and 6 months after the procedure and quantified pain subjectively on a scale from 0 to 10 (no pain and maximum pain, respectively). Results: 38 eyes were included, 15 in Group 1 and 21 in Group 2. There was a predominance of males with a mean age of 54 years. The most prevalent cause of painful blind eye was the neovascular glaucoma. Any retrobulbar injection of chlorpromazine as the intravitreal triamcinolone shown to be effective in the control of ocular pain in the eye blind study period (p <0.001). There was a 77.1% reduction in eye drops (p <0.01) after application of medication. Conclusion: Both the retrobulbar injection chlorpromazine as the intravitreal triamcinolone showed significant results in the control of ocular pain in blind eyes, and a reduction in the use of eye drops. Chlorpromazine is a low cost product, with a better adverse effect profile and showed slightly better results compared to triamcinolone. Potential bias identified in the study are the time and selection.

Glaucome néovasculaire: étiologies et difficultés liées à sa prise en charge à Brazzaville

INTRODUCTION: Le glaucome neovasculaire (GNV) est lie a une neovascularisation de l'angle iridocorneen secondaire a une hypoxie prolongee de la retine. Dans les pays occidentaux; son traitement est bien codifie et le pronostic est bien meilleur qu'a Brazzaville ou le GNV se termine souvent par une enucleation suite a une phtise hyperalgique ou a un eclatement spontane de l'oil. OBJECTIF: enumerer les principales etiologies du GNV et discuter des difficultes liees a sa prise en charge a Brazzaville. MATeRIELS ET MeTHODES: etude transversale; multicentrique (CHU/Brazzaville; Clinique Medicale de Brazzaville); realisee sur une periode de 7 ans sur la base de dossiers de patients vus pour un GNV. Le GNV etait defini par l'association d'une rubeose irienne et d'un tonus oculaire superieure a 21 mm Hg. Les parametres suivant etaient analyses: motifs de consultation; presentations cliniques; etiologies et traitements.ReSULTATS : 25 dossiers ont ete retenus (correspondant a 30 yeux souffrant de GNV). La douleur oculaire etait le principal motif de consultation (92%; 23/25 patients). La cornee etait opaque avec gonoscopie et fond d'oeil impossibles dans 83;33% des cas (25/30 yeux). Les etiologies etaient: diabete sucre (88%; 22/25 patients); occlusion de la veine centrale de la retine (12%; 3/25 patients). Perdus de vue 7/25 patients correspondant a 7/30 yeux. Le traitement consistait en enucleation (69;56%; 16/23 yeux); photocoagulation retinienne (21;74%; 5/23 yeux); et injection retrobulbaire de Chlorpromazine (8;70%; 2/23 yeux). CONCLUSION: Le diabete sucre est la principale etiologie du GNV a Brazzaville. Le manque de moyens techniques et les consultations tardives n'offrent que peu d'alternative therapeutique a l'enucleation qui reste largement malheureusement utilisee

Pars Plana Ahmed Implantation Combined with 23-gauge Vitrectomy for Refractory Neovascular Glaucoma in Diabetic Retinopathy

PURPOSE: To evaluate the efficacy and safety of a pars plana Ahmed valve implantation combined with 23-gauge sutureless vitrectomy in the treatment of patients with medically uncontrolled neovascular glaucoma (NVG) in proliferative diabetic retinopathy (PDR). METHODS: The authors retrospectively reviewed the records of 11 consecutive patients with refractory NVG in PDR who underwent a 23-gauge sutureless vitrectomy combined with pars plana placement of an Ahmed valve implant. Control of intraocular pressure (IOP), pre- and postoperative best-corrected visual acuity and the development of intra- and postoperative complications were evaluated during the follow-up. RESULTS: The mean follow-up was 12.2 months (range, 8 to 25 months). Mean preoperative IOP was 35.9 +/- 6.3 mmHg and mean postoperative IOP at the last visit was 13.3 +/- 3.2 mmHg. Control of IOP (8 to 18 mmHg) was achieved in all patients, but 91% (10 of 11 patients) needed antiglaucoma medication (mean number of medications, 1.2 +/- 0.6). Postoperative visual acuity improved in 11 eyes, and the logarithmically to the minimum angle of resolution mean visual acuity in these eyes improved from 1.67 +/- 0.61 to 0.96 +/- 0.67. The complications that occurred were transient hypotony in one case, transitory hypertension in two cases, and postoperative vitreous hemorrhage which spontaneously cleared in two cases. CONCLUSIONS: We suggest the combination of 23-gauge pars plana vitrectomy and Ahmed valve implantation is safe and effective in PDR patients with refractory NVG.

Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab

A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.

Recurrent Intraocular Pressure Elevation during Hemodialysis in a Patient with Neovascular Glaucoma

PURPOSE: To report a patient with symptomatic intraocular pressure (IOP) elevation in an eye with neovascular glaucoma (NVG) during hemodialysis. METHODS: Case report. RESULTS: Recurrent episodes of severe ocular pain and elevated IOP in the NVG eye were noted during hemodialysis in a 29-year-old man. The patient was recently diagnosed at our ophthalmology clinic with NVG due to central retinal vein occlusion. IOP was temporarily controlled after the Ahmed valve implantation. However, after the fibrous membrane developed and occluded the tip of the Ahmed valve, IOP elevation during hemodialysis recurred. Further treatments with intravenous mannitol, oral carbonic anhydrase inhibitor, topical antiglaumatic agents and subconjunctival 5-fluorouracil (5-FU) injections all failed to control relapsing pain and IOP elevation. Eventually, evisceration and hydroxyappatite implantation were performed. CONCLUSIONS: Physicians must be alert to the possibility of IOP elevation in glaucomatous eyes during hemodialysis.